CL2007003053A1 - Derivado de metastina que comprende una secuencia peptidica; medicamento que comprende el derivado; metodo para suprimir la metastasis de cancer o la proliferacion de cancer; y usos del derivado. - Google Patents

Derivado de metastina que comprende una secuencia peptidica; medicamento que comprende el derivado; metodo para suprimir la metastasis de cancer o la proliferacion de cancer; y usos del derivado.

Info

Publication number: CL2007003053A1
Authority: CL; Chile
Prior art keywords: derivative; understanding; cancer; delete; medicinal product
Prior art date: 2006-10-25

Application number

CL200703053A

Other languages

English (en)

Inventor

Asami Naoki Nishizawa Taiji

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-25

Filing date

2007-10-24

Publication date

2008-08-08

2007-10-24 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2008-08-08 Publication of CL2007003053A1 publication Critical patent/CL2007003053A1/es

Links

206010028980 Neoplasm Diseases 0.000 title 2
201000011510 cancer Diseases 0.000 title 2
206010027476 Metastases Diseases 0.000 title 1
KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
230000009401 metastasis Effects 0.000 title 1
230000035755 proliferation Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Zoology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Gynecology & Obstetrics (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Pregnancy & Childbirth (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)

CL200703053A 2006-10-25 2007-10-24 Derivado de metastina que comprende una secuencia peptidica; medicamento que comprende el derivado; metodo para suprimir la metastasis de cancer o la proliferacion de cancer; y usos del derivado. CL2007003053A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2006290536		2006-10-25
JP2007021387		2007-01-31
JP2007221911		2007-08-28

Publications (1)

Publication Number	Publication Date
CL2007003053A1 true CL2007003053A1 (es)	2008-08-08

Family

ID=38925530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703053A CL2007003053A1 (es)	2006-10-25	2007-10-24	Derivado de metastina que comprende una secuencia peptidica; medicamento que comprende el derivado; metodo para suprimir la metastasis de cancer o la proliferacion de cancer; y usos del derivado.

Country Status (33)

Country	Link
US (2)	US8765909B2 (es)
EP (1)	EP2081955B1 (es)
JP (2)	JP2010507565A (es)
KR (1)	KR101424306B1 (es)
AR (1)	AR063367A1 (es)
AU (1)	AU2007309969B2 (es)
BR (1)	BRPI0717441B8 (es)
CA (1)	CA2667537C (es)
CL (1)	CL2007003053A1 (es)
CR (1)	CR10799A (es)
CY (1)	CY1116627T1 (es)
DK (1)	DK2081955T3 (es)
EC (1)	ECSP099279A (es)
ES (1)	ES2539430T3 (es)
GE (1)	GEP20125568B (es)
HR (1)	HRP20150819T1 (es)
HU (1)	HUE025291T2 (es)
IL (1)	IL198046A (es)
JO (1)	JO3048B1 (es)
MA (1)	MA30887B1 (es)
ME (1)	ME00786B (es)
MX (1)	MX2009004148A (es)
MY (1)	MY145975A (es)
NO (1)	NO341584B1 (es)
NZ (1)	NZ576375A (es)
PE (1)	PE20081469A1 (es)
PL (1)	PL2081955T3 (es)
PT (1)	PT2081955E (es)
RS (1)	RS54083B1 (es)
SI (1)	SI2081955T1 (es)
TN (1)	TN2009000140A1 (es)
TW (1)	TWI404726B (es)
WO (1)	WO2008050897A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060241051A1 (en)	2002-12-26	2006-10-26	Chieko Kitada	Metastin derivatives and use thereof
JP4346650B2 (ja) *	2004-06-25	2009-10-21	武田薬品工業株式会社	メタスチン誘導体およびその用途
US8404643B2 (en) *	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090093615A1 (en) *	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
TWI386417B (zh)	2005-12-22	2013-02-21	Takeda Pharmaceutical	轉移抑素衍生物及其用途
US20090099334A1 (en) *	2005-12-22	2009-04-16	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
JP5279021B2 (ja) *	2006-04-26	2013-09-04	国立大学法人京都大学	Ｇｐｒ５４アゴニスト活性を有する新規化合物
TWI404726B (zh)	2006-10-25	2013-08-11	Takeda Pharmaceutical	腫瘤轉移抑制素衍生物及其用途
US8110639B2 (en) *	2006-11-17	2012-02-07	Solvay Advanced Polymers, L.L.C.	Transparent and flame retardant polysulfone compositions
US20110118172A1 (en) *	2008-04-24	2011-05-19	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
EP2275433B1 (en)	2008-04-30	2017-06-07	Kyoto University	Metastin derivative and use thereof
SI2314609T1 (sl)	2008-07-30	2017-05-31	Takeda Pharmaceutical Company Limited	Derivat metastina in njegova uporaba
US8716228B2 (en)	2009-05-27	2014-05-06	Yeda Research And Development Co. Ltd.	GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
ES2513569T3 (es) *	2010-06-25	2014-10-27	Takeda Pharmaceutical Company Limited	Formulación de liberación prolongada que comprende un derivado de metastina
EP2755690B1 (en)	2011-08-04	2020-04-01	Merck Sharp & Dohme B.V.	Kisspeptide-pentasaccharide conjugates
CN105263900B (zh) *	2013-06-12	2020-09-22	默克专利股份公司	用于治疗关节病的羟基亚乙基衍生物
WO2015112703A1 (en) *	2014-01-22	2015-07-30	The Johns Hopkins University	Compositions and methods for treating diabetes
JP6253146B2 (ja) *	2014-02-04	2017-12-27	国立大学法人山口大学	新規なペプチド誘導体及びこれを含有する医薬
EP3253774B1 (en) *	2015-02-08	2018-11-21	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Peptides for the treatment of malignant proliferative diseases
EP3650464B8 (en)	2017-07-05	2025-12-24	The General Hospital Corporation	Peptide compound and application thereof, and composition containing peptide compound
TWI795462B (zh) *	2017-11-17	2023-03-11	日商鹽野義製藥股份有限公司	光安定性及溶出性優異的醫藥製劑
JP2023521388A (ja) *	2020-04-08	2023-05-24	ラトガース，ザステートユニバーシティオブニュージャージー	脂肪肝疾患に対する修飾キスペプチン受容体作用薬
US12521455B2 (en)	2024-04-08	2026-01-13	Radionetics Oncology, Inc.	Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL74827A (en)	1984-05-21	1989-06-30	Salk Inst For Biological Studi	Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es)	1990-08-24	1992-04-01	Syntex Inc	Antagonistas de la bradiquinina
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
CN1200114A (zh)	1995-10-19	1998-11-25	武田药品工业株式会社	作为gnrh拮抗剂的喹啉衍生物
JPH09169735A (ja)	1995-10-19	1997-06-30	Takeda Chem Ind Ltd	キノリン誘導体、その製造法および用途
EP0910579A1 (en)	1996-04-19	1999-04-28	Novo Nordisk A/S	Compounds with growth hormone releasing properties
CA2283299A1 (en)	1997-03-07	1998-09-11	Human Genome Sciences, Inc.	186 human secreted proteins
JP4486187B2 (ja)	1998-10-27	2010-06-23	武田薬品工業株式会社	新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en)	1998-12-28	2003-03-04	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
KR20020016852A (ko)	1999-06-28	2002-03-06	스타르크, 카르크	종양 성장의 억제 방법
US6638906B1 (en)	1999-12-13	2003-10-28	Nobex Corporation	Amphiphilic polymers and polypeptide conjugates comprising same
AU1889101A (en)	1999-12-17	2001-06-25	Takeda Chemical Industries Ltd.	Process for producing kiss-1 peptide
HUP0500345A2 (hu)	2000-03-29	2005-07-28	Corixa Corporation	Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
WO2001075104A1 (fr)	2000-03-30	2001-10-11	Takeda Chemical Industries, Ltd.	Nouvelle proteine, adn codant pour celle-ci, et son procede de production
US7834141B1 (en)	2000-03-31	2010-11-16	Theresa Siler-Khodr	Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru)	2000-09-20	2007-12-10	Корикса Корпорейшн	Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja)	2000-11-29	2003-01-29	Takeda Chem Ind Ltd	医薬組成物およびその製造法
JP2002320496A (ja)	2001-02-26	2002-11-05	Takeda Chem Ind Ltd	新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr)	2001-04-20	2002-10-31	Takeda Chemical Industries, Ltd.	Preparations contenant un peptide
EP1391518A4 (en)	2001-05-17	2006-06-28	Shimadzu Corp	PROCESS FOR PEPTIDE MANUFACTURE
EP1428835B1 (en)	2001-09-19	2007-04-18	Takeda Pharmaceutical Company Limited	Antibody against metastin and use of the same in the diagnosis of pregnancy
AU2003201854A1 (en)	2002-01-11	2003-07-30	Takeda Chemical Industries, Ltd.	PROCESS FOR PRODUCING KiSS-1 PEPTIDE
JP2003300906A (ja)	2002-04-12	2003-10-21	Daiichi Fine Chemical Co Ltd	がん転移抑制因子の安定化
US20060035875A1 (en)	2002-10-09	2006-02-16	Yukimasa Shiotsu	Remedy for hormone-dependent cancer
JP2006513723A (ja)	2002-10-25	2006-04-27	パラダイム・セラピューティクス・リミテッド	Ｇｐｒ５４ノックアウト哺乳動物とそれを用いるスクリーニング方法
US20060241051A1 (en)	2002-12-26	2006-10-26	Chieko Kitada	Metastin derivatives and use thereof
JP4804714B2 (ja) *	2002-12-26	2011-11-02	武田薬品工業株式会社	メタスチン誘導体およびその用途
US6800611B2 (en)	2003-01-06	2004-10-05	Takeda Chemical Industries, Ltd.	Metastin derivatives and their use
KR100595364B1 (ko)	2003-02-20	2006-07-03	재단법인 목암생명공학연구소	Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
EP1604682A4 (en)	2003-03-12	2009-06-24	Takeda Chemical Industries Ltd	AGENTS IMPROVING GONADIC FUNCTION
EP1464652A1 (en)	2003-04-02	2004-10-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en)	2003-04-17	2005-01-06	Vincent Ling	Use of B7-H3 as an immunoregulatory agent
AU2004234399A1 (en)	2003-04-28	2004-11-11	Wyeth	Methods utilising G-protein coupled receptor 54
WO2004101747A2 (en)	2003-05-07	2004-11-25	The General Hospital Corporation	Identification and use of gpr54 and its ligands for reproductive disorders and contraception
EP1975153A3 (en)	2003-05-30	2010-03-31	Prozymex A/S	Protease inhibitors
BRPI0318594B8 (pt)	2003-11-03	2021-05-25	Beijing Sunbio Biotech Co Ltd	proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico
WO2005095973A2 (en)	2004-03-25	2005-10-13	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
AU2005249373A1 (en)	2004-04-23	2005-12-15	Laboratoires Serono Sa	Use of GPCR54 ligands for the treatment of infertility
JP4346650B2 (ja) *	2004-06-25	2009-10-21	武田薬品工業株式会社	メタスチン誘導体およびその用途
WO2007084211A2 (en)	2005-11-11	2007-07-26	The General Hospital Corporation	Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
TWI386417B (zh)	2005-12-22	2013-02-21	Takeda Pharmaceutical	轉移抑素衍生物及其用途
US20090099334A1 (en)	2005-12-22	2009-04-16	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US8404643B2 (en)	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090093615A1 (en)	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
BRPI0708943A2 (pt)	2006-03-20	2011-06-14	Merck & Co Inc	agonista do receptor de neuromidina u, mÉtodos para produÇço de um agonista do receptor de neuromidina u e para o tratamento de um distérbio metabàlico em um indivÍduo, uso do agonista do receptor de neuromedina u, e, composiÇço farmacÊutica
JP2009536611A (ja)	2006-03-28	2009-10-15	バイオファルミカリミテッド	ホルモン依存性障害の処置のための作用物質及びその使用
TWI404726B (zh)	2006-10-25	2013-08-11	Takeda Pharmaceutical	腫瘤轉移抑制素衍生物及其用途
WO2009044918A1 (ja)	2007-10-05	2009-04-09	Takeda Pharmaceutical Company Limited	ニューロメジンｕ誘導体
US20110118172A1 (en)	2008-04-24	2011-05-19	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
WO2010033224A1 (en)	2008-09-19	2010-03-25	Nektar Therapeutics	Polymer conjugates of kiss1 peptides

2007
- 2007-10-23 TW TW096139608A patent/TWI404726B/zh active
- 2007-10-23 JO JOP/2007/0448A patent/JO3048B1/ar active
- 2007-10-24 CL CL200703053A patent/CL2007003053A1/es unknown
- 2007-10-24 AU AU2007309969A patent/AU2007309969B2/en not_active Ceased
- 2007-10-24 AR ARP070104699A patent/AR063367A1/es active IP Right Grant
- 2007-10-24 PT PT78309036T patent/PT2081955E/pt unknown
- 2007-10-24 MX MX2009004148A patent/MX2009004148A/es active IP Right Grant
- 2007-10-24 EP EP20070830903 patent/EP2081955B1/en active Active
- 2007-10-24 HU HUE07830903A patent/HUE025291T2/en unknown
- 2007-10-24 CA CA2667537A patent/CA2667537C/en active Active
- 2007-10-24 KR KR1020097010545A patent/KR101424306B1/ko active Active
- 2007-10-24 ES ES07830903.6T patent/ES2539430T3/es active Active
- 2007-10-24 DK DK07830903.6T patent/DK2081955T3/da active
- 2007-10-24 ME MEP-2009-130A patent/ME00786B/me unknown
- 2007-10-24 WO PCT/JP2007/071169 patent/WO2008050897A1/en not_active Ceased
- 2007-10-24 BR BRPI0717441A patent/BRPI0717441B8/pt not_active IP Right Cessation
- 2007-10-24 SI SI200731649T patent/SI2081955T1/sl unknown
- 2007-10-24 PL PL07830903T patent/PL2081955T3/pl unknown
- 2007-10-24 MY MYPI20091689A patent/MY145975A/en unknown
- 2007-10-24 HR HRP20150819TT patent/HRP20150819T1/hr unknown
- 2007-10-24 GE GEAP200711265A patent/GEP20125568B/en unknown
- 2007-10-24 US US12/446,142 patent/US8765909B2/en active Active
- 2007-10-24 US US11/977,477 patent/US7786083B2/en active Active
- 2007-10-24 NZ NZ576375A patent/NZ576375A/en not_active IP Right Cessation
- 2007-10-24 JP JP2009518179A patent/JP2010507565A/ja active Pending
- 2007-10-24 RS RS20150413A patent/RS54083B1/sr unknown
- 2007-10-24 PE PE2007001444A patent/PE20081469A1/es active IP Right Grant
2009
- 2009-04-06 IL IL198046A patent/IL198046A/en active IP Right Grant
- 2009-04-15 TN TNP2009000140A patent/TN2009000140A1/fr unknown
- 2009-04-16 NO NO20091487A patent/NO341584B1/no unknown
- 2009-04-23 EC EC2009009279A patent/ECSP099279A/es unknown
- 2009-05-13 MA MA31868A patent/MA30887B1/fr unknown
- 2009-05-15 CR CR10799A patent/CR10799A/es unknown
2013
- 2013-01-11 JP JP2013004011A patent/JP5686825B2/ja not_active Expired - Fee Related
2015
- 2015-07-29 CY CY20151100668T patent/CY1116627T1/el unknown

Also Published As

Publication number	Publication date
IL198046A (en)	2014-06-30
HUE025291T2 (en)	2016-02-29
NO341584B1 (no)	2017-12-11
AU2007309969B2 (en)	2012-04-19
JO3048B1 (ar)	2016-09-05
PT2081955E (pt)	2015-07-10
JP2010507565A (ja)	2010-03-11
EP2081955B1 (en)	2015-05-06
KR20090090315A (ko)	2009-08-25
CA2667537A1 (en)	2008-05-02
GEP20125568B (en)	2012-07-10
IL198046A0 (en)	2011-08-01
US20090215700A1 (en)	2009-08-27
TW200823232A (en)	2008-06-01
RS54083B1 (sr)	2015-10-30
DK2081955T3 (da)	2015-06-15
MY145975A (en)	2012-05-31
WO2008050897A1 (en)	2008-05-02
HK1130500A1 (en)	2009-12-31
TN2009000140A1 (en)	2010-10-18
BRPI0717441B8 (pt)	2021-05-25
ES2539430T3 (es)	2015-06-30
HRP20150819T1 (hr)	2015-09-11
ME00786B (me)	2011-12-20
MX2009004148A (es)	2009-05-01
TWI404726B (zh)	2013-08-11
JP2013075913A (ja)	2013-04-25
KR101424306B1 (ko)	2014-08-01
PE20081469A1 (es)	2008-12-25
NZ576375A (en)	2011-07-29
BRPI0717441A2 (pt)	2013-11-19
ECSP099279A (es)	2009-06-30
PL2081955T3 (pl)	2015-10-30
US7786083B2 (en)	2010-08-31
MA30887B1 (fr)	2009-11-02
BRPI0717441B1 (pt)	2019-07-02
NO20091487L (no)	2009-07-07
AR063367A1 (es)	2009-01-21
AU2007309969A1 (en)	2008-05-02
CY1116627T1 (el)	2017-03-15
CR10799A (es)	2009-06-09
US8765909B2 (en)	2014-07-01
AU2007309969A2 (en)	2009-06-04
EP2081955A1 (en)	2009-07-29
JP5686825B2 (ja)	2015-03-18
CA2667537C (en)	2017-01-17
SI2081955T1 (sl)	2015-06-30
US20110059888A1 (en)	2011-03-10

Publication	Publication Date	Title
CL2007003053A1 (es)	2008-08-08	Derivado de metastina que comprende una secuencia peptidica; medicamento que comprende el derivado; metodo para suprimir la metastasis de cancer o la proliferacion de cancer; y usos del derivado.
HRP20190378T1 (hr)	2019-04-19	Prolijekovi tetrahidrokanabinola, pripravci koji sadržavaju prolijekove tetrahidrokanabinola i postupci za njihovu uporabu
CL2011003350A1 (es)	2012-06-08	Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
PT1849470T (pt)	2017-09-22	Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
DK2139490T3 (da)	2014-09-08	Diazo-bicykliske smac-mimetiske stoffer og anvendelser deraf
SMT201600225B (it)	2016-08-31	DERIVATI DI 1,2,4-TIAZOLlDIN-3-0NE E LORO USO NEL TRATTAMENTO DEL CANCRO
EP2153354A4 (en)	2012-07-18	FREE ENHANCED SEARCH PROCESSING VIA TEXT MESSAGE TRANSMISSION
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
DK2479174T3 (da)	2017-11-27	6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
PA8772101A1 (es)	2009-02-09	Imidazol-triazolopirimidinas sustituidas
CL2011002595A1 (es)	2013-10-04	Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
DK2151438T3 (da)	2012-11-26	Lægemiddel indeholdende PPAR-Deltaagonist
CL2008001334A1 (es)	2008-09-22	Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
EP2176792A4 (en)	2011-01-12	PROMOTED SEARCH
EP2910554A4 (en)	2016-06-29	BENZINDOLOCARBAZOLE DERIVATIVE MATERIAL MANUFACTURED THEREFOR FOR A LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING ELEMENT
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
EP2907803A4 (en)	2016-09-21	FLUORANTHE DERIVATIVE, FLUORESCENT WITH IT AND LIGHT ELEMENT
EP2518110A4 (en)	2014-06-25	COMPOSITION AND COMPOSITION USING LIGHT-EMITTING ITEM
EP2303946A4 (en)	2012-11-21	CONNECTORS AND MATERIALS MANUFACTURED WITH YOUR HELP
BRPI1006651A2 (pt)	2015-08-25	Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
IT1396904B1 (it)	2012-12-20	Procedimento e impianto per la fabbricazione di carte decorative e/o pannelli da pavimentazione o rivestimento di mobili, pareti, eccetera
EP2408912A4 (en)	2013-04-17	FOXM1 PEPTIDES AND VACCINES CONTAINING THEM
CL2014003148A1 (es)	2015-02-27	Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BRPI0915527A2 (pt)	2016-01-26	pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BRPI0912133A2 (pt)	2015-11-03	artigo resitente á penetração, e, uso do mesmo.